Smith & Nephew PLC Sponsored ADR Stock News

Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript

Smith & Nephew PLC has said 2025 should show its transformation plan kicking in despite ongoing woes in China after improving trading over the last year. Revenue climbed 4.7% to US$5.8 billion in the year to December 31, the medical equipment maker said Tuesday, aiding an 8.2% increase in trading profit to US$1.1 billion.

Smith+Nephew beat analysts' expectations for annual sales and profit on Tuesday, as a recovery in its U.S. knee and hip implant business, along with cost cuts, helped the medical products maker offset the impact of weak demand from China.

Smith & Nephew PLC has left itself with the mounting task of having to give investors something to cheer about after ringing the warning bell last time out. Ahead of full-year figures on Tuesday, 25 February, AJ Bell analysts noted the medical equipment maker flagged it and chief executive Deepak Nath needed to reassure.

First in market to o ffe r A djustable T ensioning T echnology * for i nsertional A chilles r econstruction and l ateral a nkle i nstability r epair

Healthcare professionals are invited to register for the livestream option as a courtesy  here

Smith & Nephew's stock has underperformed, driven by ongoing market share losses in hip and knee markets and pricing pressures in China, raising concerns about its ongoing multiyear restructuring program. The upcoming fourth quarter results may not significantly help, given ongoing market share pressure in major joints, ongoing headwinds in China, and a lack of clear growth engines. Smith & Nep...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally - have completed updated Clinical Evidence Assessments of ALLEVYN LIFE Sacrum Foam Dressings and the LEAF Patient Monitoring System. In their latest reports, ECRI upgraded its Evidence Bar ratings for both to favorable* after assessing the m...